Jim Tartaglia currently holds the position of Vice President and the Product Development Head in North America for Sanofi Pasteur. Prior to this role, he held positions of Site Head for research and Site Head for R&D at the Toronto site. Prior to joining Sanofi Pasteur, Canada, in 1999, he held the position of Executive Director of Research at Virogenetics Corporation of Troy, New York, a former subsidiary of Sanofi Pasteur. While at Virogenetics, he helped develop the poxvirus vector technology as an immunization vehicle for both veterinary and human application. Prior to joining Virogenetics in 1990, he worked as a research scientist with the New York State Department of Health and a Postdoctoral Fellow at Roche Institute of Molecular Biology in Nutley, New Jersey. He holds a Ph.D. degree from the Department of Microbiology and Immunology at the Albany Medical College, NY, USA, and a B.S. degree in biology from Bucknell University in Lewisburg, Pa, USA. Dr. Tartaglia is an inventor of over 20 patents relating to recombinant vaccines and has authored over 125 publications in the areas of molecular virology and recombinant vaccine technology. Dr. Tartaglia has been involved in the licensure of several vaccines in the human and veterinary field and was a key figure in the HIV Thai trial, RV144, which led to first demonstration that a vaccine regimen can reduce the risk of acquisition to HIV infection.
Biography Updated on 29 June 2010